Human papillomavirus episome stability is reduced by aphidicolin and controlled by DNA damage response pathways

Journal of Virology

Volumn 87, Issue 7, 2013, Pages 3979-3989

  Edwards, Terri G ^a   Helmus, Michael J ^a   Koeller, Kevin ^b   Bashkin, James K ^a,b   Fisher, Chris ^a  

^a NanoVir   (United States)

^b UNIVERSITY OF MISSOURI ST LOUIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APHIDICOLIN; ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; SMALL INTERFERING RNA; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; EPISOME; GENE LOSS; GENE SILENCING; GENETIC STABILITY; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VIRUS DNA CELL DNA INTERACTION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; APHIDICOLIN; BLOTTING, SOUTHERN; BLOTTING, WESTERN; DNA COPY NUMBER VARIATIONS; DNA DAMAGE; DNA PRIMERS; DNA-ACTIVATED PROTEIN KINASE; FLOW CYTOMETRY; GENOME, VIRAL; GENOMIC INSTABILITY; HUMANS; KERATINOCYTES; PLASMIDS; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

ATAXIA TELANGIECTASIA; HUMAN PAPILLOMAVIRUS;

EID: 84875520891     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03473-12     Document Type: Article

References (61)

1. zur Hausen H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2:342-350.
2. Stenlund A. 2003. Initiation of DNA replication: lessons from viral initiator proteins. Nat. Rev. Mol. Cell Biol. 4:777-785.
3. McBride AA, Romanczuk H, Howley PM. 1991. The papillomavirus E2 regulatory proteins. J. Biol. Chem. 266:18411-18414.
4. Garner-Hamrick PA, Fostel JM, Chien WM, Banerjee NS, Chow LT, Broker TR, Fisher C. 2004. Global effects of human papillomavirus type 18 E6/E7 in an organotypic keratinocyte culture system. J. Virol. 78:9041- 9050.
5. Moody CA, Laimins LA. 2010. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10:550 -560.
6. Bodily J, Laimins LA. 2011. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 19:33-39.
7. Woodman CB, Collins SI, Young LS. 2007. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer 7:11-22.
8. Thorland EC, Myers SL, Gostout BS, Smith DI. 2003. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 22:1225-1237.
9. Thorland EC, Myers SL, Persing DH, Sarkar G, McGovern RM, Gostout BS, Smith DI. 2000. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites. Cancer Res. 60:5916 -5921.
10. zur Hausen H. 1991. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184:9 -13.
11. Doorbar J, Parton A, Hartley K, Banks L, Crook T, Stanley M, Crawford L. 1990. Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology 178:254 -262.
12. Meyers C, Frattini MG, Hudson JB, Laimins LA. 1992. Biosynthesis ofhuman papillomavirus from a continuous cell line upon epithelial differentiation. Science 257:971-973.
13. Flores ER, Allen-Hoffmann BL, Lee D, Lambert PF. 2000. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J. Virol. 74:6622- 6631.
14. Frattini MG, Lim HB, Laimins LA. 1996. In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation- dependent late expression. Proc. Natl. Acad. Sci. U. S. A. 93:3062-3067.
15. Garner-Hamrick PA, Fisher C. 2002. HPV episomal copy number closely correlates with cell size in keratinocyte monolayer cultures. Virology 301: 334-341.
16. Hebner CM, Laimins LA. 2006. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev. Med. Virol. 16:83-97.
17. Münger K, Howley PM. 2002. Human papillomavirus immortalization and transformation functions. Virus Res. 89:213-228.
18. Bedell MA, Hudson JB, Golub TR, Turyk ME, Hosken M, Wilbanks GD, Laimins LA. 1991. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J. Virol. 65: 2254 -2260.
19. Edwards TG, Koeller KJ, Slomczynska U, Fok K, Helmus M, Bashkin JK, Fisher C. 2011. HPV episome levels are potently decreased by pyrroleimidazole polyamides. Antiviral Res. 91:177-186.
20. Jeon S, Allen-Hoffmann BL, Lambert PF. 1995. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69:2989 -2997.
21. Stubenrauch F, Hummel M, Iftner T, Laimins LA. 2000. The E8E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratinocytes. J. Virol. 74:1178 -1186.
22. Bodily JM, Mehta KP, Cruz L, Meyers C, Laimins LA. 2011. The E7 open reading frame acts in cis and in trans to mediate differentiation-dependent activities in the human papillomavirus type 16 life cycle. J. Virol. 85:8852- 8862.
23. Wilson R, Fehrmann F, Laimins LA. 2005. Role of the E1-E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31. J. Virol. 79:6732- 6740.
24. Chang YE, Pena L, Sen GC, Park JK, Laimins LA. 2002. Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J. Virol. 76:8864-8874.
25. Herdman MT, Pett MR, Roberts I, Alazawi WO, Teschendorff AE, Zhang XY, Stanley MA, Coleman N. 2006. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 27:2341-2353.
26. Chang YE, Laimins LA. 2000. Microarray analysis identifies interferoninducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 74:4174-4182.
27. Turnell AS, Grand RJ. 2012. DNA viruses and the cellular DNA-damage response. J. Gen. Virol. 93:2076 -2097.
28. Weitzman MD, Lilley CE, Chaurushiya MS. 2010. Genomes in conflict: maintaining genome integrity during virus infection. Annu. Rev. Microbiol. 64:61- 81.
29. Harper JW, Elledge SJ. 2007. The DNA damage response: ten years after. Mol. Cell 28:739 -745.
30. Stracker TH, Usui T, Petrini JH. 2009. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst) 8:1047-1054.
31. Banerjee NS, Wang HK, Broker TR, Chow LT. 2011. Human papillomavirus (HPV) E7 induces prolonged G2 following S phase reentry in differentiated human keratinocytes. J. Biol. Chem. 286:15473- 15482.
32. Fradet-Turcotte A, Bergeron-Labrecque F, Moody CA, Lehoux M, Laimins LA, Archambault J. 2011. Nuclear accumulation of the papillomavirus E1 helicase blocks S-phase progression and triggers an ATMdependent DNA damage response. J. Virol. 85:8996 -9012.
33. Moody CA, Laimins LA. 2009. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog. 5:e1000605. doi:10.1371/journal.ppat.1000605.
34. Sakakibara N, Mitra R, McBride A. 2011. The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. J. Virol. 85:8981- 8995.
35. Arienti KL, Brunmark A, Axe FU, McClure K, Lee A, Blevitt J, Neff DK, Huang L, Crawford S, Pandit CR, Karlsson L, Breitenbucher JG. 2005. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J. Med. Chem. 48:1873-1885.
36. Ashwell S, Zabludoff S. 2008. DNA damage detection and repair pathways- recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin. Cancer Res. 14:4032- 4037.
37. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GC. 2004. Identification and characterization of a novel and specific inhibitor of the ataxiatelangiectasia mutated kinase ATM. Cancer Res. 64:9152-9159.
38. Tavecchio M, Munik JM, Cano C, Newell DR, Curtin NJ. 2012. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemother. Pharmacol. 69:155-164.
39. Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, Ma S, Moler EJ, Ni ZJ, Lopes de Menezes DE, Hibner B, Gesner TG, Schwartz GK. 2007. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin. Cancer Res. 13:591- 602.
40. McBride AA, Sakakibara N, Stepp WH, Jang MK. 2012. Hitchhiking on host chromatin: how papillomaviruses persist. Biochim. Biophys. Acta 1819:820-825.
41. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. 2009. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog. 5:e1000318. doi:10.1371/journal.ppat.1000318.
42. Byun TS, Pacek M, Yee MC, Walter JC, Cimprich KA. 2005. Functional uncoupling ofMCMhelicase and DNA polymerase activities activates the ATR-dependent checkpoint. Genes Dev. 19:1040 -1052.
43. Smith J, Tho LM, Xu N, Gillespie DA. 2010. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 108:73-112.
44. Angeletti PC, Kim K, Fernandes FJ, Lambert PF. 2002. Stable replication of papillomavirus genomes in Saccharomyces cerevisiae. J. Virol. 76: 3350-3358.
45. Egawa N, Nakahara T, Ohno S, Narisawa-Saito M, Yugawa T, Fujita M, Yamato K, Natori Y, Kiyono T. 2012. The E1 protein of human papillomavirus type 16 is dispensable for maintenance replication of the viral genome. J. Virol. 86:3276 -3283.
46. Kim K, Lambert PF. 2002. E1 protein of bovine papillomavirus 1 is not required for the maintenance of viral plasmid DNA replication. Virology 293:10 -14.
47. Pittayakhajonwut D, Angeletti PC. 2010. Viral trans-factor independent replication of human papillomavirus genomes. Virol. J. 7:123. doi:10.1186 /1743-422X-7-123.
48. Durkin SG, Glover TW. 2007. Chromosome fragile sites. Annu. Rev. Genet. 41:169 -192.
49. Glover TW, Arlt MF, Casper AM, Durkin SG. 2005. Mechanisms of common fragile site instability. Hum. Mol. Genet. 14(Suppl 2):R197- R205.
50. Mrasek K, Schoder C, Teichmann AC, Behr K, Franze B, Wilhelm K, Blaurock N, Claussen U, Liehr T, Weise A. 2010. Global screening and extended nomenclature for 230 aphidicolin-inducible fragile sites, including 61 yet unreported ones. Int. J. Oncol. 36:929 -940.
51. Casper AM, Nghiem P, Arlt MF, Glover TW. 2002. ATR regulates fragile site stability. Cell 111:779 -789.
52. Kumari D, Somma V, Nakamura AJ, Bonner WM, D'Ambrosio E, Usdin K. 2009. The role of DNA damage response pathways in chromosome fragility in Fragile X syndrome. Nucleic Acids Res. 37:4385- 4392.
53. Durkin SG, Arlt MF, Howlett NG, Glover TW. 2006. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene 25:4381- 4388.
54. Hori T, Takahashi E, Murata M. 1988. Nature of distamycin A-inducible fragile sites. Cancer Genet. Cytogenet. 34:189 -194.
55. Ozeri-Galai E, Schwartz M, Rahat A, Kerem B. 2008. Interplay between ATM and ATR in the regulation of common fragile site stability. Oncogene 27:2109 -2117.
56. Gamper AM, Choi S, Matsumoto Y, Banerjee D, Tomkinson AE, Bakkenist CJ. 2012. ATM protein physically and functionally interacts with proliferating cell nuclear antigen to regulate DNA synthesis. J. Biol. Chem. 287:12445-12454.
57. White JS, Choi S, Bakkenist CJ. 2010. Transient ATM kinase inhibition disrupts DNA damage-induced sister chromatid exchange. Sci. Signal. 3:ra44. doi:10.1126/scisignal.2000758.
58. Daniel JA, Pellegrini M, Lee BS, Guo Z, Filsuf D, Belkina NV, You Z, Paull TT, Sleckman BP, Feigenbaum L, Nussenzweig A. 2012. Loss of ATM kinase activity leads to embryonic lethality in mice. J. Cell Biol. 198:295-304.
59. Yamamoto K, Wang Y, Jiang W, Liu X, Dubois RL, Lin CS, Ludwig T, Bakkenist CJ, Zha S. 2012. Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice. J. Cell Biol. 198:305-313.
60. Gillespie KA, Mehta KP, Laimins LA, Moody CA. 2012. Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers. J. Virol. 86:9520 -9526.
61. Seedorf K, Krammer G, Durst M, Suhai S, Rowekamp WG. 1985. Human papillomavirus type 16 DNA sequence. Virology 145:181-185.